(2018) 38:e198201
Keywords: obstructive sleep apnea, anti-obesity medications, obesity, tirzepatide, semaglutide Introduction Obstructive sleep apnea and obesity are two interrelated health conditions that have become increasingly prevalent worldwide, posing significant public health challenges
Effect of semaglutide treatment on a proteomic signature of CVD risk A 27-protein score has previously been described that predicts secondary CVD risk over 4 years, based on large multicohort data and using the same SomaScan technology used in our study 22 (Extended Data Table 1)
Additional information Supported by Grants KO1 NR010548, RO1 HL69170, the Children's Healthcare of Atlanta Center for Developmental Lung Biology, and Grant UL1 RR025008 from the Clinical and Translational Science Award Program Rights and permissions About this article Cite this article Fitzpatrick, A., Teague, W., Burwell, L
Many individuals choose IV hydration as part of a wellness routine to help support hydration and nutrient intake